What is it about?
lasting analgesic efficacy, tolerability, influence on life quality, and chronicity stage of the novel prolonged release (PR) opioid, tapentadol, in 30 outpatients. At follow-ups, the investigated outcomes showed an overall statistically significant (Wilcoxon signed-rank test) improvement and remained stable over time, as did the health status and chronicity stage. Adverse effects were limited, transitory, and tolerable.
Featured Image
Why is it important?
Twelve weeks of PR tapentadol in outpatients with moderate/severe chronic musculoskeletal pain showed satisfactory analgesic efficacy and tolerability, and had a positive influence on life quality and chronicity stage.
Perspectives
The results are robust enough to warrant a subsequent study with a larger sample and a longer observation period.
Dr Boaz Gedaliahu Samolsky Dekel
Universita degli Studi di Bologna
Read the Original
This page is a summary of: Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain, Pain and Therapy, January 2015, Springer Science + Business Media,
DOI: 10.1007/s40122-014-0030-6.
You can read the full text:
Contributors
The following have contributed to this page
